Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Aug 22;7(16):4400-4402.
doi: 10.1182/bloodadvances.2023010722.

CNL and aCML are prognostically distinct: a large National Cancer Database analysis

Douglas Tremblay  1 , Dahniel Sastow  1 , John Mascarenhas  1
Affiliations
Comment

CNL and aCML are prognostically distinct: a large National Cancer Database analysis

Douglas Tremblay et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: D.T. receives contracted research funding to his institution from CTI Biopharma, Astellas Pharma, and Gilead, and consulting fees from CTI Biopharma, Novartis, AbbVie, Sierra Oncology, GlaxoSmithKline (GSK), and Cogent Biosciences. J.M. receives contracted research funding to his institution from AbbVie, CTI BioPharma Corp, Celgene/Bristol Myers Squibb, Geron Corporation, Incyte Corporation, Kartos Therapeutics, Novartis, PharmaEssentia, and Roche; is on the data and safety monitoring board at Karyopharm Therapeutics; and has received consulting fees from Galecto, Sierra Oncology, GSK, Imago BioSciences, and Constellation Pharmaceuticals/MorphoSys.

Figures

Figure 1.
Figure 1.
Kaplan-Meier curve of the OS of patients with aCML and CNL. Patients with aCML (red line) had a significantly shorter OS than patients with CNL (blue line).
See this image and copyright information in PMC

Comment in

Comment on

  • CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
    Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, Martínez-Ávila JC, Hernández-Boluda JC, Ferrer-Marín F, Radia DH, Mora E, Francis S, González-Martínez T, Goddard K, Pérez-Encinas M, Narayanan S, Raya JM, Singh V, Gutiérrez X, Toth P, Amat-Martínez P, Mcilwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufián L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martínez-López J, Ayala R, Cross NCP. Carreño-Tarragona G, et al. Blood Adv. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204. Blood Adv. 2023. PMID: 36375042 Free PMC article.

References

    1. Carreno-Tarragona G, Alvarez-Larran A, Harrison C, et al. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Blood Adv. 2023;7(9):1672–1681. - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. - PMC - PubMed
    1. American College of Surgeons. National Cancer Data Base. https://www.facs.org/quality-programs/cancer/ncdb/about
    1. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–2651. - PMC - PubMed
    1. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313–317. - PubMed

MeSH terms